Drug profile · INN
sargramostim
IMREPLYS
sargramostim (IMREPLYS) is a granulocyte-macrophage colony-stimulating factor receptor agonist. Current US regulatory status: approved.
Drug details — sargramostim
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L03)
- Route
- —
- Patents
- 0
- Programs
- 8
- Data quality
- 0.83
Quick answer
sargramostim (IMREPLYS) is a granulocyte-macrophage colony-stimulating factor receptor agonist. Current US regulatory status: approved.
Key facts
Mechanism of action
Granulocyte-macrophage colony-stimulating factor receptor agonist
Primary target: Granulocyte-macrophage colony-stimulating factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is sargramostim?
sargramostim (IMREPLYS) is a granulocyte-macrophage colony-stimulating factor receptor agonist. Current US regulatory status: approved.
What is the brand name for sargramostim?
IMREPLYS is a marketed brand name for sargramostim. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sargramostim?
sargramostim has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.